Study design and rationale of "Synergistic Effect of Combination Therapy with Cilostazol and ProbUcol on Plaque Stabilization and Lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

BACKGROUND: Probucol, a cholesterol-lowering agent that paradoxically also lowers high-density lipoprotein cholesterol has been shown to prevent progression of atherosclerosis. The antiplatelet agent cilostazol, which has diverse antiatherogenic properties, has also been shown to reduce restenosis i...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ko, Young-Guk, Kim, Byeong-Keuk, Lee, Byoung Kwon, Kang, Woong Chol, Choi, Seung Hyuk, Kim, Sang Wook, Lee, Jong Ho, Lee, Myoungsook, Honda, Yasuhiro, Fitzerald, Peter J, Shim, Won-Heum
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2011
Ämnen:
Study Protocol
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033833/
https://ncbi.nlm.nih.gov/pubmed/21226953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-12-10
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk